IN184589B
(enEXAMPLES)
*
|
1996-10-16 |
2000-09-09 |
Alza Corp |
|
US20020182258A1
(en)
*
|
1997-01-22 |
2002-12-05 |
Zycos Inc., A Delaware Corporation |
Microparticles for delivery of nucleic acid
|
US7258869B1
(en)
|
1999-02-08 |
2007-08-21 |
Alza Corporation |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
|
DE19940748A1
(de)
*
|
1999-08-27 |
2001-03-01 |
Hugo Seinfeld |
Arzneimittel enthaltend xenogene Oligo- oder/und Polyribonukleotide
|
WO2001037804A2
(en)
*
|
1999-11-22 |
2001-05-31 |
Universal Preservation Technologies, Inc. |
Preservation and formulation of bioactive materials
|
EP1263461A4
(en)
*
|
2000-03-07 |
2009-08-12 |
Merck & Co Inc |
ADENOVIRUS FORMULATIONS
|
US7456009B2
(en)
*
|
2000-03-07 |
2008-11-25 |
Merck & Co., Inc. |
Adenovirus formulations
|
US7153472B1
(en)
|
2000-11-22 |
2006-12-26 |
Quadrant Drug Delivery Limited |
Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
|
CA2451953A1
(en)
*
|
2001-06-28 |
2003-04-24 |
Microchips, Inc. |
Methods for hermetically sealing microchip reservoir devices
|
WO2003048665A1
(en)
|
2001-12-03 |
2003-06-12 |
Massachusetts Institute Of Technology |
Microscale lyophilization and drying methods for the stabilization of molecules
|
NZ534377A
(en)
*
|
2002-03-13 |
2008-04-30 |
Collagenex Pharm Inc |
Water-based topical delivery system consisting of cholesterol, fatty acids water and a phospholipid/ceramide portion.
|
EP1528940B1
(en)
*
|
2002-08-16 |
2011-04-13 |
Microchips, Inc. |
Controlled release device and method
|
AU2003278766A1
(en)
*
|
2002-09-04 |
2004-03-29 |
Microchips, Inc. |
Method and device for the controlled delivery of parathyroid hormone
|
GB2410497B
(en)
*
|
2002-09-27 |
2006-11-22 |
Powderject Res Ltd |
Nucleic acid coated particles
|
AU2003284018A1
(en)
|
2002-10-04 |
2004-05-04 |
Microchips, Inc. |
Medical device for neural stimulation and controlled drug delivery
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
JP5591434B2
(ja)
|
2002-12-20 |
2014-09-17 |
ゼリス ファーマシューティカルズ インコーポレイテッド |
皮内注射方法
|
AU2004229465B2
(en)
*
|
2003-04-09 |
2010-04-29 |
The United States Of America Department Of Veterans Affairs |
Compositions and methods related to production of erythropoietin
|
JP4734236B2
(ja)
*
|
2003-04-25 |
2011-07-27 |
ボストン サイエンティフィック サイムド,インコーポレイテッド |
固形型の薬物の貯蔵及び制御された放出のための装置及びその製造方法
|
US7892205B2
(en)
*
|
2003-06-06 |
2011-02-22 |
Boston Scientific Scimed, Inc. |
Device and method for delivering micronized therapeutic agents in the body
|
US8095197B2
(en)
*
|
2003-11-03 |
2012-01-10 |
Microchips, Inc. |
Medical device for sensing glucose
|
CA2569375A1
(en)
*
|
2004-06-01 |
2006-08-17 |
Microchips, Inc. |
Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant
|
WO2006015299A2
(en)
*
|
2004-07-30 |
2006-02-09 |
Microchips, Inc. |
Multi-reservoir device for transdermal drug delivery and sensing
|
US7772182B2
(en)
*
|
2004-08-05 |
2010-08-10 |
Alza Corporation |
Stable suspension formulations of erythropoietin receptor agonists
|
US20060029551A1
(en)
*
|
2004-08-05 |
2006-02-09 |
Kui Liu |
Stable particle formulations of erythropoietin receptor agonists
|
AU2005279729B2
(en)
*
|
2004-09-01 |
2010-12-02 |
Microchips, Inc. |
Multi-cap reservoir devices for controlled release or exposure of reservoir contents
|
AU2005285279B2
(en)
|
2004-09-10 |
2012-03-22 |
Becton, Dickinson And Company |
Reconstituting infusion device
|
AU2006208131A1
(en)
|
2005-01-25 |
2006-08-03 |
Microchips, Inc. |
Control of drug release by transient modification of local microenvironments
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
EP1962586B1
(en)
*
|
2005-12-22 |
2017-07-12 |
Oakwood Laboratories L.L.C. |
Sublimable sustained release delivery system and method of making same
|
NZ572003A
(en)
|
2006-05-30 |
2010-07-30 |
Intarcia Therapeutics Inc |
Two-piece, internal-channel osmotic delivery system flow modulator with spiral fluid channel
|
EP3421031A1
(en)
|
2006-08-09 |
2019-01-02 |
Intarcia Therapeutics, Inc |
Osmotic delivery systems and piston assemblies
|
EP2134353B1
(en)
*
|
2007-03-30 |
2016-11-16 |
Helix Biopharma Corp. |
Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
|
WO2008133908A2
(en)
|
2007-04-23 |
2008-11-06 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
HUE043228T2
(hu)
|
2007-06-22 |
2019-08-28 |
Univ Texas |
Stabil szubmikron peptid vagy protein részecskék képzése vékonyfilm fagyasztással
|
DK2240155T3
(da)
*
|
2008-02-13 |
2012-09-17 |
Intarcia Therapeutics Inc |
Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
|
EP2376522A4
(en)
|
2008-11-16 |
2013-12-25 |
Univ Texas |
HIGHLY CONCENTRATED LOW VISCOSITY SUSPENSIONS
|
US9283184B2
(en)
*
|
2008-11-24 |
2016-03-15 |
Massachusetts Institute Of Technology |
Methods and compositions for localized agent delivery
|
PL2462246T3
(pl)
|
2009-09-28 |
2018-02-28 |
Intarcia Therapeutics, Inc |
Szybkie ustalenie i/lub zakończenie dostarczania leku zasadniczo w stanie równowagi dynamicznej
|
CN103096934A
(zh)
*
|
2010-03-09 |
2013-05-08 |
詹森生物科技公司 |
非水性高浓度低粘度混悬剂
|
US20110223208A1
(en)
|
2010-03-09 |
2011-09-15 |
Beth Hill |
Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
AU2011229235B2
(en)
|
2010-03-17 |
2014-08-14 |
Novaliq Gmbh |
Pharmaceutical composition for treatment of increased intraocular pressure
|
WO2012012460A1
(en)
|
2010-07-19 |
2012-01-26 |
Xeris Pharmaceuticals, Inc. |
Stable glucagon formulations for the treatment of hypoglycemia
|
EP2444063A1
(en)
|
2010-10-20 |
2012-04-25 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the delivery of active ingredients
|
EP2462921A1
(en)
|
2010-11-11 |
2012-06-13 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the treatment of a posterior eye disease
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
ES2621304T3
(es)
|
2011-03-10 |
2017-07-03 |
Xeris Pharmaceuticals, Inc. |
Formulaciones estables para inyección parenteral de fármacos peptídicos
|
WO2012160179A2
(en)
|
2011-05-25 |
2012-11-29 |
Novaliq Gmbh |
Topical pharmaceutical composition based on semifluorinated alkanes
|
CN103561724B
(zh)
|
2011-05-25 |
2016-06-29 |
诺瓦利克有限责任公司 |
给药给甲的药物组合物
|
DK2773331T3
(en)
|
2011-10-31 |
2016-03-14 |
Xeris Pharmaceuticals Inc |
Formulations for the treatment of diabetes
|
PL2806886T3
(pl)
|
2012-01-23 |
2017-08-31 |
Novaliq Gmbh |
Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach
|
US9125805B2
(en)
|
2012-06-27 |
2015-09-08 |
Xeris Pharmaceuticals, Inc. |
Stable formulations for parenteral injection of small molecule drugs
|
CN104755073B
(zh)
|
2012-09-12 |
2017-12-26 |
诺瓦利克有限责任公司 |
半氟化烷烃组合物
|
JP6352266B2
(ja)
|
2012-09-12 |
2018-07-04 |
ノバリック ゲーエムベーハー |
半フッ化アルカンの混合物を含む組成物
|
US9505737B2
(en)
|
2013-01-11 |
2016-11-29 |
Corsair Pharma, Inc. |
Treprostinil derivative compounds and methods of using same
|
US9371264B2
(en)
|
2013-01-11 |
2016-06-21 |
Corsair Pharma, Inc. |
Treprostinil derivative compounds and methods of using same
|
US9018162B2
(en)
|
2013-02-06 |
2015-04-28 |
Xeris Pharmaceuticals, Inc. |
Methods for rapidly treating severe hypoglycemia
|
CA2899089C
(en)
*
|
2013-03-15 |
2021-10-26 |
Biogen Ma Inc. |
Factor ix polypeptide formulations
|
CA2918419C
(en)
|
2013-07-23 |
2022-05-03 |
Novaliq Gmbh |
Stabilized antibody compositions
|
US8986732B2
(en)
|
2013-08-12 |
2015-03-24 |
Helix Biopharma Corporation |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
US10159646B2
(en)
|
2013-08-12 |
2018-12-25 |
Altum-Avro Pharma Partnership |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
IL312865B2
(en)
|
2013-09-11 |
2025-06-01 |
Eagle Biologics Inc |
Liquid protein formulations containing viscosity-lowering agents
|
ES2904276T3
(es)
|
2013-09-27 |
2022-04-04 |
Massachusetts Inst Technology |
Nanoestructuras de proteínas biológicamente activas sin vehículo
|
MA39779A
(fr)
*
|
2014-03-24 |
2017-02-01 |
Biogen Ma Inc |
Formulations de facteur ix lyophilisées
|
JP6561109B2
(ja)
|
2014-07-16 |
2019-08-14 |
コルセア ファーマ インコーポレイテッド |
トレプロスチニル誘導体化合物およびその使用方法
|
CN106573106B
(zh)
|
2014-08-06 |
2021-06-22 |
Xeris药物公司 |
用于皮内和/或皮下注射糊剂的注射器、试剂盒和方法
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
US11471479B2
(en)
|
2014-10-01 |
2022-10-18 |
Eagle Biologics, Inc. |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
JP6993235B2
(ja)
|
2015-06-03 |
2022-01-13 |
インターシア セラピューティクス,インコーポレイティド |
インプラントの設置及び撤去システム
|
US9649364B2
(en)
|
2015-09-25 |
2017-05-16 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic formulations in aprotic polar solvents
|
US9394227B1
(en)
|
2015-06-17 |
2016-07-19 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
US9643911B2
(en)
|
2015-06-17 |
2017-05-09 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
CA2995212A1
(en)
|
2015-08-12 |
2017-02-16 |
Massachusetts Institute Of Technology |
Cell surface coupling of nanoparticles
|
US11590205B2
(en)
|
2015-09-25 |
2023-02-28 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
|
PT3355990T
(pt)
|
2015-09-30 |
2019-09-11 |
Novaliq Gmbh |
Compostos semifluorados e as suas composições
|
PL3722274T3
(pl)
|
2015-09-30 |
2023-12-04 |
Novaliq Gmbh |
Związki semifluorowane
|
US10501517B2
(en)
|
2016-05-16 |
2019-12-10 |
Intarcia Therapeutics, Inc. |
Glucagon-receptor selective polypeptides and methods of use thereof
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
CN109715196A
(zh)
|
2016-06-13 |
2019-05-03 |
转矩医疗股份有限公司 |
用于促进免疫细胞功能的组合物和方法
|
PT3442480T
(pt)
|
2016-06-23 |
2019-12-23 |
Novaliq Gmbh |
Método de administração tópica
|
PL3515420T3
(pl)
|
2016-09-22 |
2024-04-08 |
Novaliq Gmbh |
Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek
|
JP6869336B2
(ja)
|
2016-09-23 |
2021-05-12 |
ノバリック ゲーエムベーハー |
シクロスポリンを含む眼科用組成物
|
US10835580B2
(en)
|
2017-01-03 |
2020-11-17 |
Intarcia Therapeutics, Inc. |
Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
WO2018193093A1
(en)
|
2017-04-21 |
2018-10-25 |
Novaliq Gmbh |
Iodine compositions
|
WO2018206656A1
(en)
|
2017-05-12 |
2018-11-15 |
Novaliq Gmbh |
Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
|
EP3624846B1
(en)
|
2017-05-16 |
2024-08-07 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan
|
KR20240036128A
(ko)
|
2017-06-02 |
2024-03-19 |
엑스에리스 파머수티클스, 인크. |
침전 방지 저분자 약물 제제
|
CN111432836A
(zh)
|
2017-09-05 |
2020-07-17 |
转矩医疗股份有限公司 |
治疗性蛋白质组合物及其制备和使用方法
|
CN111372566A
(zh)
|
2017-09-27 |
2020-07-03 |
诺瓦利克有限责任公司 |
用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
|
CN120022260A
(zh)
|
2017-10-04 |
2025-05-23 |
诺瓦利克有限责任公司 |
包含f6h8的眼用组合物
|
US11576893B2
(en)
|
2018-03-02 |
2023-02-14 |
Novaliq Gmbh |
Pharmaceutical compositions comprising nebivolol
|
JP2021522219A
(ja)
|
2018-04-27 |
2021-08-30 |
ノバリック ゲーエムベーハー |
緑内障の治療のためのタフルプロストを含む眼科用組成物
|
WO2019217637A1
(en)
*
|
2018-05-09 |
2019-11-14 |
Biomatrica, Inc. |
Stabilization of proteins in biological samples
|
CA3112031A1
(en)
|
2018-10-12 |
2020-04-16 |
Novaliq Gmbh |
Ophthalmic composition for treatment of dry eye disease
|
KR20210125032A
(ko)
|
2019-02-05 |
2021-10-15 |
린디 바이오사이언시스, 아이엔씨. |
세포 배양 성분 및 액체 세포 배양 배지로부터 이를 단리하는 방법
|
WO2020165132A1
(en)
|
2019-02-13 |
2020-08-20 |
Novaliq Gmbh |
Compositions and methods for the treatment of ocular neovascularization
|
US20220409705A1
(en)
|
2019-12-06 |
2022-12-29 |
Guangzhou Bioseal Biotech Co., Ltd. |
Flowable fibrinogen thrombin paste
|
WO2022109294A2
(en)
*
|
2020-11-20 |
2022-05-27 |
Team Medical Llc |
Rna stabilization
|
WO2023044455A2
(en)
*
|
2021-09-16 |
2023-03-23 |
Team Medical Llc |
Rna stabilization
|